少突胶质细胞在帕金森病中的研究进展

doi:10.19803/j.1672-8629.2021.04.01

摘要/Abstract

摘要： 少突胶质细胞（oligodendrocytes, OLs）是中枢神经系统（central nervous system, CNS）中的神经胶质细胞之一,由少突胶质前体细胞（oligodendrocyte precursor cells, OPCs）分化而成,能够形成绝缘性髓鞘,促进轴突动作电位的快速传导。帕金森病（parkinson’s disease, PD）是以黑质纹状体多巴胺能神经元丢失为特征的CNS退行性疾病,其病理标志为嗜酸性路易小体（Lewy bodies, LBs）和路易神经突（Lewy neurites, LNs）的聚集,其中,LBs的主要成分为错误折叠的α-突触核蛋白（α-synuclein, α-syn）。研究发现,许多PD患者具有脱髓鞘、白质病变、OLs损伤等伴随病理表现,此外,OLs中聚集的α-syn能够加速神经元的死亡,提示OLs在PD的发生发展过程中起着重要的作用。因此,深入研究OLs与PD的关系有助于进一步探索PD的发病机制,为发现新的PD治疗靶点提供新思路,有望通过维持髓鞘完整性、保证OLs的正常功能而干预PD的病理进展。

关键词: 少突胶质细胞, 帕金森病, 髓鞘病变, α-突触核蛋白

Abstract: Derived from oligodendrocyte precursor cells (OPCs), Oligodendrocytes (OLs), one of the neuroglial cells in the central nervous system (CNS), can form insulating myelin sheaths and promote the rapid conduction of axonal action potentials. Parkinson's disease (PD), characterized by the loss of dopaminergic neurons in the substantia nigra and striatum, is a CNS degenerative disease and its pathological hallmark is the accumulation of Lewy neurites and the eosinophilic spherical bodies named Lewy bodies(LBs), the main component of which is misfolded α-synuclein(α-uclein, α-syn). Recently, studies have found that many PD patients have potential pathological manifestations such as demyelination, white matter lesions, and OLs damage. At the same time, the accumulation of α-syn in OLs can accelerate the death of neurons, which further suggests that OLs might play an important role in the development of PD. Therefore, the deep study of the relationship between OLs and PD will help to further explore the pathogenesis of PD and provide a new idea for the discovery of new therapeutic targets of PD. What's more, maintaining the integrity of the myelin sheath and ensuring the normal function of OLs are expected to interfere with the pathological progress of PD.

Key words: oligodendrocytes, Parkinson's disease, demyelination, α-synuclein

中图分类号:

R994.1

薄茹雪, 陈乃宏, 苑玉和. 少突胶质细胞在帕金森病中的研究进展[J]. 中国药物警戒, 2021, 18(4): 301-305.

BO Ruxue, CHEN Naihong, YUAN Yuhe. Research Progress on Oligodendrocytes in Parkinson's Disease[J]. Chinese Journal of Pharmacovigilance, 2021, 18(4): 301-305.

参考文献

[1] Butt AM, Papanikolaou M, Rivera A.Physiology of oligodendroglia[J]. Adv Exp Med Biol, 2019, 1175: 117-128.
[2] Xin W, Chan JR.Myelin plasticity: sculpting circuits in learning and memory[J]. Nature Reviews Neuroscience, 2020, 21(12): 682-694.
[3] Jankovic J.Parkinson's disease: clinical features and diagnosis[J]. J Neurol Neurosurg Psychiatry, 2008, 79(4): 368-76.
[4] Chaudhuri KR, Healy DG, Schapira AHV.Non-motor symptoms of Parkinson's disease: diagnosis and management[J]. The Lancet Neurology, 2006, 5(3): 235-245.
[5] Chen LF, Xue LJ, Zheng JL, et al.PPARβ/δ agonist alleviates NLRP3 inflammasome-mediated neuroinflammation in the MPTP mouse model of Parkinson’s disease[J]. Behavioural Brain Research, 2019, 356: 483-489.
[6] Zhang Z, Chen WL.Research progress of oligodendrocytes in neuro- degenerative diseases[J]. Journal of Yunnan University (Natural Science Edition)(云南大学学报(自然科学版)), 2019, 41(2): 404-410.
[7] Saab AS, Tzvetanova ID, Nave KA.The role of myelin and oligodendrocytes in axonal energy metabolism[J]. Curr Opin Neurobiol, 2013, 23(6): 1065-1072.
[8] Monje M.Myelin plasticity and nervous system function[J]. Annu Rev Neurosci, 2018, 41: 61-76.
[9] Fünfschilling U, Supplie LM, Mahad D, et al.Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity[J]. Nature, 2012, 485(7399): 517-521.
[10] Lee Y, Morrison BM, Li Y, et al.Oligodendroglia metabolically support axons and contribute to neurodegeneration[J]. Nature, 2012, 487(7408): 443-448.
[11] Morrison BM, Lee Y, Rothstein JD.Oligodendroglia: metabolic supporters of axons[J]. Trends in Cell Biology, 2013, 23(12): 644-651.
[12] Tang XY, Lan MH, Zhang M, et al.Effect of nitric oxide to axonal degeneration in multiple sclerosis via downregulating monocarboxylate transporter 1 in oligodendrocytes[J]. Nitric Oxide, 2017, 67: 75-80.
[13] Jeffries MA, Urbanek K, Torres L, et al.ERK1/2 activation in preexisting oligodendrocytes of adult mice drives new myelin synthesis and enhanced CNS function[J]. The Journal of Neuroscience, 2016, 36(35): 9186-9200.
[14] Sampaio-Baptista C, Johansen-Berg H.White matter plasticity in the adult brain[J]. Neuron, 2017. 96(6): 1239-1251.
[15] McKenzie IA, Ohayon D, Li HL, et al. Motor skill learning requires active central myelination[J]. Science, 2014, 346(6207): 318-322.
[16] Lin X, Ohayon D, McKenzie IA, et al. Rapid production of new oligodendrocytes is required in the earliest stages of motor-skill learning[J]. Nat Neurosci, 2016, 19(9): 1210-1217.
[17] Berto S, Mendizabal I, Usui N, et al.Accelerated evolution of oligodendrocytes in the human brain[J]. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116(48): 24334-24342.
[18] Hentrich T, Wassouf Z, Ehrhardt C, et al.Increased expression of myelin-associated genes in frontal cortex of SNCA overexpressing rats and Parkinson's disease patients[J]. Aging, 2020, 12(19): 18889-18906.
[19] Yu S, Li X, Liu G, et al.Extensive nuclear localization of alpha-synuclein in normal rat brain neurons revealed by a novel monoclonal antibody[J]. Neuroscience, 2007, 145(2): 539-555.
[20] Emamzadeh FN.Alpha-synuclein structure, functions, and interactions[J]. Journal of Research in Medical Sciences, 2016, 21(1): 29-29.
[21] Karpowicz RJ, Trojanowski JQ, Lee VMY.Transmission of α-synuclein seeds in neurodegenerative disease: recent develop-ments[J]. Laboratory Investigation, 2019, 99(7): 971-981.
[22] Burré J, Sharma M, Südhof TC.Cell biology and pathophysiology of α-synuclein[J]. Cold Spring Harbor Perspectives in Medicine, 2018, 8(3) :a024091.
[23] Kasongo DW, Leo GD, Vicario N, et al. Chronic α-synuclein accumulation in rat hippocampus induces Lewy bodies formation and specific cognitive impairments[J]. eNeuro, 2020, 7(3) : ENEURO. 0009-20. 2020.
[24] Recasens A, Ulusoy A, Kahle PJ et al. In vivo models of alpha-synuclein transmission and propagation[J]. Cell Tissue Res, 2018, 373(1):183-193.
[25] Rodriguez L, Marano MM, Tandon A.Import and export of misfolded α-synuclein[J]. Front Neurosci, 2018, 12: 344.
[26] Chaturvedi RK, Beal MF.Mitochondrial approaches for neurop- rotection[J]. Ann N Y Acad Sci, 2008, 1147(1): 395-412.
[27] Exner N, Lutz AK, Haass C, et al.Mitochondrial dysfunction in Parkinson's disease: molecular mechanisms and pathophysiological consequences[J]. The EMBO Journal, 2012, 31(14): 3038-3062.
[28] Han QW, Chen Y, Chen NH.et al.MPTP-induced PD-like pathological changes in mice liver[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2021, 18(1): 1-10.
[29] Choi W S, Palmiter RD, Xia ZG.Loss of mitochondrial complex I activity potentiates dopamine neuron death induced by microtubule dysfunction in a Parkinson’s disease model[J]. Journal of Cell Biology, 2011, 192(5): 873-882.
[30] Di Maio R, Barrett PJ, Hoffman EK, et al.α-Synuclein binds to TOM20 and inhibits mitochondrial protein import in Parkinson’s disease[J]. Science Translational Medicine, 2016, 8(342): 78.
[31] Gupta V, Garg RK, Khattri S.Levels of IL-8 and TNF-α decrease in Parkinson's disease[J]. Neurological research, 2016, 38(2): 98-102.
[32] Lindqvist D, Kaufman E, Brundin L, et al.Non-motor symptoms in patients with Parkinson's disease correlations with inflammatory cytokines in serum[J]. PloS One, 2012, 7(10): e47387.
[33] Hickman S, Lzzy S, Sen P, et al.Microglia in neurodegeneration[J]. Nature Neuroscience, 2018, 21(10): 1359-1369.
[34] von Euler Chelpin M, Vorup-Jensen T. Targets and mechanisms in prevention of Parkinson's disease through immunomodulatory treatments[J]. Scandinavian Journal of Immunology, 2017, 85(5): 321-330.
[35] Wang R, Ouyang M, Zhang P, et al.Relationship between inflammatory factors expressed by activation of substantia nigra striatum microglia and dopamine content in Parkinson's disease mice[J]. Chinese Journal of Gerontology(中国老年学杂志), 2014, 34(10): 2768-2770.
[36] Bryois J, Skene NG, Hansen TF, et al.Genetic identification of cell types underlying brain complex traits yields insights into the etiology of parkinson's disease[J]. Nature Genetics, 2020, 52(5): 482-493.
[37] Dean DC 3rd, Sojkova J, Hurley S, et al. Alterations of myelin content in Parkinson's disease: a cross-sectional neuroimaging study[J]. PloS One, 2016, 11(10): e0163774.
[38] Annese V, Barcia C, Ros-Bernal F, et al.Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism[J]. Neuropathol Appl Neurobiol, 2013, 39(2): 132-143.
[39] Takagi S, Hayakawa N, Kimoto H, et al.Damage to oligodendrocytes in the striatum after MPTP neurotoxicity in mice[J]. Journal of Neural Transmission, 2007, 114(12): 1553-1557.
[40] Han F, Perrin RJ, Wang Q, et al.Neuroinflammation and myelin status in Alzheimer's disease, Parkinson's disease, and normal aging brains: a small sample study[J]. Parkinson's Disease, 2019, 2019: 7975407
[41] Rodriguez-Diehl R, Vilas D, Bargalló N, et al.Co-morbid demyelinating lesions and atypical clinical features in a patient with Parkinson's disease[J]. Parkinsonism & Related Disorders, 2019, 62: 242-245.
[42] Pozorski V, Oh JM, Adluru N, et al.Longitudinal white matter microstructural change in parkinson's disease[J]. Human Brain Mapping, 2018, 39(10): 4150-4161.
[43] Alieva AK, Zyrin VS, Rudenok MM, et al.Whole-transcriptome analysis of mouse models with MPTP-induced early stages of Parkinson's disease reveals stage-specific response of transcriptome and a possible role of myelin-linked genes in neurodegeneration[J]. Molecular Neurobiology, 2018, 55(9): 7229-7241.
[44] Guan XJ, Huang PY, Zeng QL, et al.Quantitative susceptibility mapping as a biomarker for evaluating white matter alterations in Parkinson's disease[J]. Brain Imaging and Behavior, 2019, 13(1): 220-231.
[45] Ubhi K, Rockenstein E, Mante M, et al.Neurodegeneration in a transgenic mouse model of multiple system atrophy is associated with altered expression of oligodendroglial-derived neurotrophic factors[J]. The Journal of Neuroscience, 2010, 30(18): 6236-6246.
[46] Yazawa I, Giasson BI, Sasaki R, et al.Mouse model of multiple system atrophy α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration[J]. Neuron, 2005, 45(6): 847-859.
[47] Grigoletto J, Pukaβ K, Gamliel A, et al.Higher levels of myelin phospholipids in brains of neuronal α-Synuclein transgenic mice precede myelin loss[J]. Acta Neuropathologica Communications, 2017, 5(1): 37.
[48] Halliday GM, Stevens CH.Glia: initiators and progressors of pathology in Parkinson's disease[J]. Movement Disorders, 2011, 26(1): 6-17.
[49] Braak H, Tredici KD.Poor and protracted myelination as a contributory factor to neurodegenerative disorders[J]. Neurobiology of Aging, 2004, 25(1): 19-23.
[50] Wakabayashi K, Hayashi S, Yoshimoto M, et al.NACP/α-synuclein-positive filamentous inclusions in astrocytes and oligodendrocytes of Parkinson's disease brains[J]. Acta Neuropathologica, 2000, 99(1): 14-20.
[51] Ray A, Katoch P, Jain N, et al. Dileucine-like motifs in the C-terminal tail of connexin32 control its endocytosis and assembly into gap junctions[J]. Journal of Cell Science, 2018, 131(5): jcs207340.
[52] Reyes JF, Sackmann C, Hoffmann A, et al.Binding of α-synuclein oligomers to Cx32 facilitates protein uptake and transfer in neurons and oligodendrocytes[J]. Acta Neuropathologica, 2019, 138(1): 23-47.